The 26th International Symposium on Microsomes and Drug Oxidations

Dr. Lingling Zhang is currently a Senior Director in the DMPK Department at WuXi AppTec. She specializes in radiolabeled synthesis and ADME studies to advance the development of novel drug candidates, including small molecules, peptides, ADCs, and oligonucleotides. With over 16 years of industry experience, Dr. Zhang has contributed to the approval of dozens of new drugs. She holds more than 10 patents, has authored 7 peer-reviewed publications, and participated in drafting the NMPA guidance on Human Radiolabeled Mass Balance Studies.

Dr. Xiaoqi Wang completed her undergraduate studies in Chemistry at Nanjing University and later earned her PhD from Rutgers University, specializing in the metabolic pathways of small molecules and related PK/PD research. Before joining WuXi AppTec DMPK, she gained valuable experience in antibody analytics within the CMC field. This unique cross-disciplinary background enables her to address the unique DMPK challenges of complex bioconjugates. In her current role as a study director, she specializes in designing and overseeing pharmacokinetic studies for novel therapeutic modalities, with a particular focus on oligonucleotides, AOCs, and ADCs.

Dr. Hong Zhang is a principal expert in the DMPK Department at WuXi AppTec, where he leads a specialized metabolite identification (MetID) group. Bringing over a decade of experience in preclinical drug development, he specializes in optimizing in vitro metabolic systems and elucidating the metabolic profiles of complex novel modalities, including oligonucleotides, antibody-oligonucleotide conjugates (AOCs), and PROTACs, using advanced LC-HRMS techniques.